These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9103496)

  • 1. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.
    Fossa AA; DePasquale MJ; Morrone J; Zorn SH; Bryce D; Lowe JA; McLean S
    J Pharmacol Exp Ther; 1997 Apr; 281(1):180-7. PubMed ID: 9103496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cholecystokinin octapeptide on rat cardiac function and the receptor mechanism.
    Zhao XY; Ling YL; Meng AH; Shan BE; Zhang JL
    Sheng Li Xue Bao; 2002 Jun; 54(3):239-43. PubMed ID: 12075472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of rats. Part A.
    Wiśniewska RJ
    Pol J Pharmacol; 1998; 50(3):203-12. PubMed ID: 9861628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cholecystokinin peptides and GV 150013, a selective cholecystokininB receptor antagonist, on electrically evoked endogenous GABA release from rat cortical slices.
    Ferraro L; Beani L; Trist D; Reggiani A; Bianchi C
    J Neurochem; 1999 Nov; 73(5):1973-81. PubMed ID: 10537055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of diabetic rats. Part B.
    Wiśniewska RJ
    Pol J Pharmacol; 1998; 50(3):213-23. PubMed ID: 9861629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of cholecystokinin-A receptors.
    Povoski SP; Zhou W; Longnecker DS; Roebuck BD; Bell RH
    Cancer Res; 1993 Sep; 53(17):3925-9. PubMed ID: 8358719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cholecystokinin (CCK-33) and its fragments, C-terminal octapeptide (CCK-8) and C-terminal tetrapeptide (CCK-4), on the circulatory system of diabetic rats.
    Fiedorowicz RJ; Wiśniewski K
    Pol J Pharmacol Pharm; 1989; 41(6):561-72. PubMed ID: 2485904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of cholecystokinin receptor sites in guinea-pig cortical membranes using [125I]Bolton Hunter-cholecystokinin octapeptide.
    Lin CW; Miller T
    J Pharmacol Exp Ther; 1985 Mar; 232(3):775-80. PubMed ID: 2983069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel CCK analogues and bombesin: a detailed analysis between phosphoinositide breakdown and high-dose inhibition of pancreatic enzyme secretion in three rodent species.
    Bianchi BR; Miller TR; Witte DG; Lin CW
    J Pharmacol Exp Ther; 1994 Feb; 268(2):996-1002. PubMed ID: 7509394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
    Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
    Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
    Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C-mediated inhibition of transmembrane signalling through CCK(A) and CCK(B) receptors.
    Smeets RL; Fouraux MA; van Emst-de Vries SE; De Pont JJ; Willems PH
    Br J Pharmacol; 1998 Mar; 123(6):1189-97. PubMed ID: 9559904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
    Corringer PJ; Weng JH; Ducos B; Durieux C; Boudeau P; Bohme A; Roques BP
    J Med Chem; 1993 Jan; 36(1):166-72. PubMed ID: 8421283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
    Abelson JL; Nesse RM
    Biol Psychiatry; 1994 Jul; 36(2):73-83. PubMed ID: 7948449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opposite effects of CCK(B) agonists in grooming behaviour in rats: further evidence for two CCK(B) subsites.
    Ladurelle N; Sebret A; Garbay C; Roques BP; Daugé V
    Br J Pharmacol; 1998 Jul; 124(6):1091-8. PubMed ID: 9720778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of central nervous system cholecystokinin receptors stimulates respiration in the cat.
    Gillis RA; Quest JA; Pagani FD; Souza JD; Da Silva AM; Jensen RT; Garvey TQ; Hamosh P
    J Pharmacol Exp Ther; 1983 Feb; 224(2):408-14. PubMed ID: 6296361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
    Bignon E; Bachy A; Boigegrain R; Brodin R; Cottineau M; Gully D; Herbert JM; Keane P; Labie C; Molimard JC; Olliero D; Oury-Donat F; Petereau C; Prabonnaud V; Rockstroh MP; Schaeffer P; Servant O; Thurneyssen O; Soubrié P; Pascal M; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1999 May; 289(2):742-51. PubMed ID: 10215648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.